Description: Caribou is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for devastating human diseases.
We are a clinical-stage biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.
Our next-generation CRISPR genome-editing technology enables superior specificity and precision. Our patented chRDNA (CRISPR hybrid RNA-DNA) technology allows for complex genome editing, including multiplex gene knockout and insertion, while maintaining genomic integrity.
Learn about chRDNA
Hyperspeed Ventures - Accelerate the Future
Maverick Ventures - Home
CRISPR 2022
Hyperspeed Ventures - Accelerate the Future
Caribou Biosciences | Developing Sophisticated Allogeneic Cell Therapies